Half-year report · HY
3341.TEDINET S100X3D6
Period2025-04-01 → 2025-09-30
Filed2025-11-14
StandardJapan GAAP
ConsolidatedYes
Data checks14 of 14 passed
Key figures · 44
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥191.6bn | 2025-04-01 → 2025-09-30 | Cons. | Net sales |
| Revenue | ¥360.5bn | 2024-04-01 → 2025-03-31 | Cons. | Net sales (5-year summary) |
| Revenue | ¥175.6bn | 2024-04-01 → 2024-09-30 | Cons. | Net sales |
| Operating income | ¥4.2bn | 2025-04-01 → 2025-09-30 | Cons. | Operating income |
| Operating income | ¥423m | 2024-04-01 → 2024-09-30 | Cons. | Operating income |
| Ordinary income | ¥4.2bn | 2025-04-01 → 2025-09-30 | Cons. | Ordinary income |
| Ordinary income | ¥6.9bn | 2024-04-01 → 2025-03-31 | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥772m | 2024-04-01 → 2024-09-30 | Cons. | Ordinary income |
| Profit before tax | ¥2.0bn | 2025-04-01 → 2025-09-30 | Cons. | Income before income taxes |
| Profit before tax | ¥762m | 2024-04-01 → 2024-09-30 | Cons. | Income before income taxes |
| Net income (owners) | ¥1.1bn | 2025-04-01 → 2025-09-30 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥1.4bn | 2024-04-01 → 2025-03-31 | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | −¥43m | 2024-04-01 → 2024-09-30 | Cons. | Profit loss attributable to owners of parent |
| Net income | ¥1.1bn | 2025-04-01 → 2025-09-30 | Cons. | Profit loss |
| Net income | −¥43m | 2024-04-01 → 2024-09-30 | Cons. | Profit loss |
| Total assets | ¥210.3bn | at 2025-09-30 | Cons. | Assets |
| Total assets | ¥197.1bn | at 2025-03-31 | Cons. | Assets |
| Total assets | ¥204.1bn | at 2024-09-30 | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥150.5bn | at 2025-09-30 | Cons. | Liabilities |
| Total liabilities | ¥138.0bn | at 2025-03-31 | Cons. | Liabilities |
| Net assets / equity | ¥59.8bn | at 2025-09-30 | Cons. | Net assets |
| Net assets / equity | ¥59.1bn | at 2025-03-31 | Cons. | Net assets |
| Net assets / equity | ¥57.9bn | at 2024-09-30 | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥16.5bn | at 2025-09-30 | Cons. | Cash and deposits |
| Cash and deposits | ¥27.5bn | at 2025-03-31 | Cons. | Cash and deposits |
| Cash & equivalents | ¥16.5bn | at 2025-09-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥27.5bn | at 2025-03-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥26.4bn | at 2024-09-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥26.0bn | at 2024-03-31v | Cons. | Cash and cash equivalents |
| Operating cash flow | −¥5.4bn | 2025-04-01 → 2025-09-30 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | ¥8.8bn | 2024-04-01 → 2025-03-31 | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | ¥1.6bn | 2024-04-01 → 2024-09-30 | Cons. | Net cash provided by used in operating activities |
| Investing cash flow | −¥3.9bn | 2025-04-01 → 2025-09-30 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥9.9bn | 2024-04-01 → 2025-03-31 | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥6.0bn | 2024-04-01 → 2024-09-30 | Cons. | Net cash provided by used in investment activities |
| Financing cash flow | −¥1.6bn | 2025-04-01 → 2025-09-30 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | ¥2.5bn | 2024-04-01 → 2025-03-31 | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | ¥4.8bn | 2024-04-01 → 2024-09-30 | Cons. | Net cash provided by used in financing activities |
| EPS (basic) | ¥37.06 | 2025-04-01 → 2025-09-30 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥46.54 | 2024-04-01 → 2025-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥-1.44 | 2024-04-01 → 2024-09-30 | Cons. | Basic earnings loss per share (5-year summary) |
| Equity ratio | 28.4% | at 2025-09-30 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 30.0% | at 2025-03-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 28.3% | at 2024-09-30 | Cons. | Equity to asset ratio (5-year summary) |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 36
| Segment | Item | Period | Value |
|---|---|---|---|
| Reconciling Itemsreconciling | revenue | 2025-04-01 → 2025-09-30 | −¥6.5bn |
| Reconciling Itemsreconciling | revenue intersegment | 2025-04-01 → 2025-09-30 | −¥6.5bn |
| Reconciling Itemsreconciling | segment profit | 2025-04-01 → 2025-09-30 | −¥3.4bn |
| Dispensing Pharmacy Businessreportable segment | revenue | 2025-04-01 → 2025-09-30 | ¥172.0bn |
| Dispensing Pharmacy Businessreportable segment | revenue external | 2025-04-01 → 2025-09-30 | ¥172.0bn |
| Dispensing Pharmacy Businessreportable segment | segment profit | 2025-04-01 → 2025-09-30 | ¥7.3bn |
| Medical Professional Staffing And Placement Businessreportable segment | revenue | 2025-04-01 → 2025-09-30 | ¥5.7bn |
| Medical Professional Staffing And Placement Businessreportable segment | revenue external | 2025-04-01 → 2025-09-30 | ¥5.7bn |
| Medical Professional Staffing And Placement Businessreportable segment | revenue intersegment | 2025-04-01 → 2025-09-30 | ¥9m |
| Medical Professional Staffing And Placement Businessreportable segment | segment profit | 2025-04-01 → 2025-09-30 | ¥388m |
| Pharmaceutical Manufacturing And Sales Businessreportable segment | revenue | 2025-04-01 → 2025-09-30 | ¥20.4bn |
| Pharmaceutical Manufacturing And Sales Businessreportable segment | revenue external | 2025-04-01 → 2025-09-30 | ¥14.0bn |
| Pharmaceutical Manufacturing And Sales Businessreportable segment | revenue intersegment | 2025-04-01 → 2025-09-30 | ¥6.5bn |
| Pharmaceutical Manufacturing And Sales Businessreportable segment | segment profit | 2025-04-01 → 2025-09-30 | −¥122m |
| Total Of Reportable Segments And Otherssegment total | revenue | 2025-04-01 → 2025-09-30 | ¥198.1bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2025-04-01 → 2025-09-30 | ¥191.6bn |
| Total Of Reportable Segments And Otherssegment total | revenue intersegment | 2025-04-01 → 2025-09-30 | ¥6.5bn |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2025-04-01 → 2025-09-30 | ¥7.5bn |
| Reconciling Itemsreconciling | revenue | 2024-04-01 → 2024-09-30 | −¥6.6bn |
| Reconciling Itemsreconciling | revenue intersegment | 2024-04-01 → 2024-09-30 | −¥6.6bn |
| Reconciling Itemsreconciling | segment profit | 2024-04-01 → 2024-09-30 | −¥4.2bn |
| Dispensing Pharmacy Businessreportable segment | revenue | 2024-04-01 → 2024-09-30 | ¥156.6bn |
| Dispensing Pharmacy Businessreportable segment | revenue external | 2024-04-01 → 2024-09-30 | ¥156.6bn |
| Dispensing Pharmacy Businessreportable segment | segment profit | 2024-04-01 → 2024-09-30 | ¥4.5bn |
| Medical Professional Staffing And Placement Businessreportable segment | revenue | 2024-04-01 → 2024-09-30 | ¥6.0bn |
| Medical Professional Staffing And Placement Businessreportable segment | revenue external | 2024-04-01 → 2024-09-30 | ¥5.9bn |
| Medical Professional Staffing And Placement Businessreportable segment | revenue intersegment | 2024-04-01 → 2024-09-30 | ¥122m |
| Medical Professional Staffing And Placement Businessreportable segment | segment profit | 2024-04-01 → 2024-09-30 | ¥766m |
| Pharmaceutical Manufacturing And Sales Businessreportable segment | revenue | 2024-04-01 → 2024-09-30 | ¥19.6bn |
| Pharmaceutical Manufacturing And Sales Businessreportable segment | revenue external | 2024-04-01 → 2024-09-30 | ¥13.1bn |
| Pharmaceutical Manufacturing And Sales Businessreportable segment | revenue intersegment | 2024-04-01 → 2024-09-30 | ¥6.5bn |
| Pharmaceutical Manufacturing And Sales Businessreportable segment | segment profit | 2024-04-01 → 2024-09-30 | −¥652m |
| Total Of Reportable Segments And Otherssegment total | revenue | 2024-04-01 → 2024-09-30 | ¥182.2bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2024-04-01 → 2024-09-30 | ¥175.6bn |
| Total Of Reportable Segments And Otherssegment total | revenue intersegment | 2024-04-01 → 2024-09-30 | ¥6.6bn |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2024-04-01 → 2024-09-30 | ¥4.6bn |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 529
| Item | Context | Value | Unit |
|---|---|---|---|
| Cash and cash equivalents | Prior1YearInstant | 27463000000 | JPY |
| Cash and cash equivalents | Prior1InterimInstant | 26424000000 | JPY |
| Cash and cash equivalents | InterimInstant | 16494000000 | JPY |
| Salaries and allowances sga | Prior1InterimDuration | 3277000000 | JPY |
| Salaries and allowances sga | InterimDuration | 3128000000 | JPY |
| Directors compensations sga | Prior1InterimDuration | 229000000 | JPY |
| Directors compensations sga | InterimDuration | 237000000 | JPY |
| Provision for bonuses sga | Prior1InterimDuration | 832000000 | JPY |
| Provision for bonuses sga | InterimDuration | 1061000000 | JPY |
| Retirement benefit expenses sga | Prior1InterimDuration | 118000000 | JPY |
| Retirement benefit expenses sga | InterimDuration | 104000000 | JPY |
| Provision for directors retirement benefits sga | Prior1InterimDuration | 8000000 | JPY |
| Provision for directors retirement benefits sga | InterimDuration | 7000000 | JPY |
| Research and development expenses sga | Prior1InterimDuration | 1733000000 | JPY |
| Research and development expenses sga | InterimDuration | 1342000000 | JPY |
| Rent expenses sga | Prior1InterimDuration | 1402000000 | JPY |
| Rent expenses sga | InterimDuration | 810000000 | JPY |
| Consumption taxes sga | Prior1InterimDuration | 12276000000 | JPY |
| Consumption taxes sga | InterimDuration | 13608000000 | JPY |
| Revenues from external customers | Prior1InterimDuration_jpcrp040300-ssr_E05422-000DispensingPharmacyBusinessReportableSegmentsMember | 156569000000 | JPY |
| Revenues from external customers | Prior1InterimDuration_jpcrp040300-ssr_E05422-000PharmaceuticalManufacturingAndSalesBusinessReportableSegmentsMember | 13105000000 | JPY |
| Revenues from external customers | Prior1InterimDuration_jpcrp040300-ssr_E05422-000MedicalProfessionalStaffingAndPlacementBusinessReportableSegmentsMember | 5899000000 | JPY |
| Revenues from external customers | Prior1InterimDuration_TotalOfReportableSegmentsAndOthersMember | 175575000000 | JPY |
| Revenues from external customers | Prior1InterimDuration_ReconcilingItemsMember | － | JPY |
| Revenues from external customers | Prior1InterimDuration | 175575000000 | JPY |
| Transactions with other segments | Prior1InterimDuration_jpcrp040300-ssr_E05422-000DispensingPharmacyBusinessReportableSegmentsMember | － | JPY |
| Transactions with other segments | Prior1InterimDuration_jpcrp040300-ssr_E05422-000PharmaceuticalManufacturingAndSalesBusinessReportableSegmentsMember | 6464000000 | JPY |
| Transactions with other segments | Prior1InterimDuration_jpcrp040300-ssr_E05422-000MedicalProfessionalStaffingAndPlacementBusinessReportableSegmentsMember | 122000000 | JPY |
| Transactions with other segments | Prior1InterimDuration_TotalOfReportableSegmentsAndOthersMember | 6586000000 | JPY |
| Transactions with other segments | Prior1InterimDuration_ReconcilingItemsMember | -6586000000 | JPY |
| Transactions with other segments | Prior1InterimDuration | － | JPY |
| Net sales | Prior1InterimDuration_jpcrp040300-ssr_E05422-000DispensingPharmacyBusinessReportableSegmentsMember | 156569000000 | JPY |
| Net sales | Prior1InterimDuration_jpcrp040300-ssr_E05422-000PharmaceuticalManufacturingAndSalesBusinessReportableSegmentsMember | 19570000000 | JPY |
| Net sales | Prior1InterimDuration_jpcrp040300-ssr_E05422-000MedicalProfessionalStaffingAndPlacementBusinessReportableSegmentsMember | 6021000000 | JPY |
| Net sales | Prior1InterimDuration_TotalOfReportableSegmentsAndOthersMember | 182161000000 | JPY |
| Net sales | Prior1InterimDuration_ReconcilingItemsMember | -6586000000 | JPY |
| Net sales | Prior1InterimDuration | 175575000000 | JPY |
| Operating income | Prior1InterimDuration_jpcrp040300-ssr_E05422-000DispensingPharmacyBusinessReportableSegmentsMember | 4509000000 | JPY |
| Operating income | Prior1InterimDuration_jpcrp040300-ssr_E05422-000PharmaceuticalManufacturingAndSalesBusinessReportableSegmentsMember | -652000000 | JPY |
| Operating income | Prior1InterimDuration_jpcrp040300-ssr_E05422-000MedicalProfessionalStaffingAndPlacementBusinessReportableSegmentsMember | 766000000 | JPY |
| Operating income | Prior1InterimDuration_TotalOfReportableSegmentsAndOthersMember | 4623000000 | JPY |
| Operating income | Prior1InterimDuration_ReconcilingItemsMember | -4200000000 | JPY |
| Operating income | Prior1InterimDuration | 423000000 | JPY |
| Revenues from external customers | InterimDuration_jpcrp040300-ssr_E05422-000DispensingPharmacyBusinessReportableSegmentsMember | 171991000000 | JPY |
| Revenues from external customers | InterimDuration_jpcrp040300-ssr_E05422-000PharmaceuticalManufacturingAndSalesBusinessReportableSegmentsMember | 13974000000 | JPY |
| Revenues from external customers | InterimDuration_jpcrp040300-ssr_E05422-000MedicalProfessionalStaffingAndPlacementBusinessReportableSegmentsMember | 5658000000 | JPY |
| Revenues from external customers | InterimDuration_TotalOfReportableSegmentsAndOthersMember | 191624000000 | JPY |
| Revenues from external customers | InterimDuration_ReconcilingItemsMember | － | JPY |
| Revenues from external customers | InterimDuration | 191624000000 | JPY |
| Transactions with other segments | InterimDuration_jpcrp040300-ssr_E05422-000DispensingPharmacyBusinessReportableSegmentsMember | － | JPY |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 14 of 14 passed
| balance sheet identity | pass |
| balance sheet identity | pass rounding |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |